PREPARED STATEMENT OF

THE FEDERAL TRADE COMMISSION

on

DECEPTIVE MARKETING OF DIETARY SUPPLEMENTS

FTC ENFORCEMENT ACTIVITIES

Before the

SPECIAL COMMITTEE ON AGING

UNITED STATES SENATE

Washington, D.C.

May 26, 2010
In these pay-for-delay patent settlements, also known as exclusion or reverse-payment 1

settlements, the brand-name drug firm pays its potential generic drug competitor to abandon a

patent challenge and delay entering the market with a lower-cost generic product. The FTC

estimates that such deals, by denying consumers access to lower-priced, generic drugs, cost

Americans $3.5 billion a year.

The FTC has brought cases, for example, against fake charities that take advantage of 2

seniors’ generosity and against companies that offer worthless medical discount cards. See, e.g.,

FTC v. Marleau, No. C09-5289BHS (W.D. Wash. final order June 18, 2009) (for-profit

company soliciting for sham police, fire and veterans non-profit charitable organizations); FTC

v. 6554962 Canada Inc., No. 08-C-2309 (N.D. Ill. default judgment and order Aug. 19, 2009)

(bogus medical or drug discount plans offered by defendants pretending to be calling from the

Social Security Administration, Medicare, or a consumer’s bank). The FTC also seeks to

address fraud against seniors through education and outreach, in partnership with the AARP.

1

I. Introduction

The Federal Trade Commission (“FTC” or “Commission”) submits this statement to

Chairman Kohl, Ranking Member Corker, and Members of the Special Committee on Aging. 

The statement details recent FTC enforcement efforts to protect consumers from false or

misleading claims about dietary supplement products. The Commission appreciates the

opportunity to submit this statement for the record.

The Federal Trade Commission works to prevent unfair competition and protect

consumers, including older Americans, from unfair or deceptive practices in the marketplace. 

As part of its antitrust efforts, the Commission has made it a priority to lower prescription drug

costs for seniors by stopping pay-for-delay deals in the pharmaceutical industry. In addition, 1

many of the FTC’s consumer protection efforts have sought to address marketing scams that

prey disproportionately on seniors. Marketing of unproven cures or treatments for various 2

health conditions is a prime example of fraud impacting older Americans, and is a priority for

FTC enforcement. This statement focuses specifically on the Commission’s active law
The Commission’s authority in this area derives from Section 5 of the Federal Trade 3

Commission Act, which prohibits “unfair or deceptive acts or practices in or affecting

commerce,” and Section 12, which prohibits the false advertisement of “food, drugs, devices,

services, or cosmetics.” 15 U.S.C. §§ 45, 52.

“NBJ Reviews the $25 Billion U.S. Supplement Market,” Nutrition Business Journal 4

(Oct. 16, 2009).

Id. 5

2

enforcement program to combat such fraud in the dietary supplement marketplace. The agency 3

coordinates these efforts closely with the Food and Drug Administration (“FDA”), and draws on

the expertise of other government authorities, including the Office of Dietary Supplements of the

National Institutes of Health (“NIH/ODS”).

The dietary supplement industry continues to represent a substantial and growing

segment of the consumer healthcare market. U.S. sales were an estimated $25 billion last year, a

six percent increase over the previous year. In fact, market analysts suggest that the downturn 4

in the economy has actually led to increased spending on supplements as consumers attempt to

manage their own healthcare and avoid expensive doctor visits and prescription medications.

5

Given this trend, it is more critical than ever that the Commission work to ensure that consumers

are getting truthful and accurate information, backed by solid scientific evidence, about dietary

supplements. 

This statement will explain how the FTC coordinates with the FDA, describe how the

FTC identifies targets and brings enforcement actions, and also highlight recent FTC

enforcement and consumer outreach efforts.

II. Coordination with FDA

The FTC and FDA have concurrent jurisdiction over dietary supplements and other
See Working Agreement Between FTC and FDA, 3 Trade Reg. Rep. (CCH) ¶ 9,859.01 6

(1971), http://www.ftc.gov/bcp/menus/resources/guidance/36FR18539.PDF.

The FTC and FDA, for instance, worked together to provide clear and consistent 7

guidance to the supplement industry on how to adequately substantiate advertising and labeling

claims. See Guidance for Industry: Substantiation for Dietary Supplement Claims Made Under

Section 403(r)(6) of the Federal Food, Drug, and Cosmetic Act (FDA Dkt. No. 2004-D-0303)

(Dec. 2008), http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/

GuidanceDocuments/DietarySupplements/ucm073200.htm. In issuing this guidance, the FDA

noted that it was “modeled on, and complements” guidance on claim substantiation provided in

the FTC’s “Dietary Supplements: An Advertising Guide for Industry” (Apr. 2001),

http://www.ftc.gov/bcp/edu/pubs/business/adv/bus09.shtm.

As part of the exchange of information, FDA compliance and law enforcement 8

personnel have access to the FTC’s secure, online complaint database, Consumer Sentinel,

which received over one million consumer complaints in 2009. The FTC staff obtains

information from FDA records on adverse events reported for the dietary supplement industry

and on labeling notifications filed with FDA by supplement manufacturers.

Staff of the FTC’s Bureau of Consumer Protection (including the Division of 9

Advertising Practices and the Division of Enforcement), FDA’s Center for Food Safety and

Applied Nutrition (“CFSAN”) and Center for Drug Evaluation Research (“CDER”), as well as

the Department of Justice’s Office of Consumer Litigation, participate on these calls..

3

health and nutrition products. The two agencies work closely to police the marketplace for false

or unsubstantiated claims and for products or marketing practices that present safety concerns. 

Under a longstanding liaison agreement, the FTC has primary authority over the advertising of 6

foods, including dietary supplements, while FDA has primary responsibility for the labeling of

those products. Despite differences in statutory authority, the two agencies have successfully

coordinated enforcement policy.7

The FTC and FDA staff share access to each other’s databases on supplement marketing

activities and have daily informal interaction on cases. In addition, the two agencies coordinate 8

more formally through monthly telephone conferences. This coordination enhances the ability 9

of both the FTC and FDA to identify the worst offenders and to formulate a more effective plan
One example of a coordinated effort using all of these tools is the action against

10

Seasilver USA, Inc. for the marketing of a supplement purported to treat or cure cancer, AIDS,

diabetes, and 650 other diseases. FTC v. Seasilver USA, Inc., No. CV-S-0676-RHL-LRL (D.

Nev. final order Mar. 4, 2004). After the FTC obtained a temporary restraining order and asset

freeze and the FDA seized the defendants’ product, the FTC reached a settlement with the

defendants that included $4.5 million in consumer redress. The FDA’s companion settlement

included the destruction of $5.3 million worth of misbranded supplements.

4

to stop fraud and deception, using the strongest tools available to each agency. The FTC, for

example, has the power to compel supplement companies to provide documents relating to the

substantiation of claims. When appropriate, the FTC can also take quick action in federal court

to obtain a temporary restraining order, appointment of a receiver to take control of a fraudulent

business, and an asset freeze. The FDA has the power to conduct seizures and order the

destruction of misbranded product.10

III. FTC Enforcement Program

Over the past decade, the Commission has filed well over 100 law enforcement actions

challenging claims about the efficacy or safety of a wide variety of supplements. The

Commission has focused its enforcement on national advertising campaigns for products with

unproven benefits, products promoted to treat or cure serious diseases, products that may present

significant safety concerns to consumers, and products that are deceptively marketed to

vulnerable populations, such as children or the elderly.

A. Case Selection, Enforcement Process, and Remedies

Potential cases come to the FTC’s attention from a number of different sources, including

complaints from consumers (through the Consumer Sentinel Network), competitors, consumer

health advocates, industry self-regulatory groups (such as the National Advertising Division of

the Council of Better Business Bureaus), agencies (e.g., FDA, NIH/ODS, and state attorneys
Section 20 of the FTC Act provides the Commission with the authority to issue a CID 11

to compel the production of records, answers to interrogatories, or the taking of testimony

whenever the agency “has reason to believe that any person may be in possession, custody, or

control of any documentary material or tangible things, or may have any information, relevant to

unfair or deceptive acts or practices.” 15 U.S.C. § 57b-1(c)(1). The FTC may bring an action in

federal court to compel a CID recipient’s compliance with a CID. 

The staff has the option initially to request documents and information through the use

12

of a voluntary “access letter” in the place of a CID.

5

general), and Congress. In addition, the FTC staff routinely monitors major television and print

media, as well as newer forms of marketing like digital and viral marketing, to identify national

advertising campaigns that are likely to have the most substantial consumer impact. The staff

also watches for new trends by reading the trade press, attending industry trade shows, and

checking consumer complaint databases. This allows the staff to quickly identify the latest fad

weight loss ingredient or spot a surge in products to treat specific diseases. Finally, the

Commission works with FDA and foreign law enforcement partners to identify specific health

problems that may be the subject of particularly widespread fraud by unscrupulous online

marketers and then identifies specific targets by conducting coordinated Internet surfs. 

Once the staff has identified a target that appears to be making unfounded claims, it

opens an investigation and issues civil investigative demands (“CIDs”) to compel the production

of documents and information by the supplement marketer and others with relevant

information. The staff uses this powerful investigative tool to obtain marketing and labeling 11

materials, sales information, and relevant substantiation materials. Dietary supplement 12

investigations often involve an assessment of the scientific evidence related to a claimed health

benefit. In many instances, the staff will contract with a scientific expert in the relevant field to
In addition, the FTC staff routinely consults with FDA in assessing the scientific

13

validity of a claimed supplement benefit.

In both administrative cases and federal court cases, the advertiser frequently elects to

14

settle the charges by entering into a consent agreement or stipulated order without admitting

liability. In some instances, where the deceptive practice is limited in scope, duration, or

severity and quickly corrected, the FTC staff may issue a public closing letter instead. The letter

typically outlines the nature of the FTC’s concerns and explains why formal action was not

taken. See, e.g., Pharmavite LLC (FTC staff closing letter addressing overstated cholesterol

reduction claims for NatureMade CholestOff) (Apr. 16, 2009),

http://www.ftc.gov/os/closings/090416cholestoffclosingletter.pdf.

15 U.S.C. § 45(m)(1)(B). 15

See, e.g., United States v. QVC, Inc., No. 2:04-CV-01276-JF (E.D. Pa. final order Mar.

16

4, 2009) ($6 million payment for consumer redress and a $1.5 million civil penalty for claims

involving weight loss supplements and other health products); United States v. Bayer Corp., No.

07-01(HAA) (D.N.J. final order Jan. 3, 2007) ($3.2 million civil penalty for claims involving

One-A-Day WeightSmart multivitamin).

15 U.S.C. § 53(b). 17

6

help assess the adequacy of the substantiation for the claim.13

If formal action is warranted, the FTC can proceed either administratively or in federal

court. Administrative orders typically include cease-and-desist provisions covering the specific 14

challenged claims, along with broader “fencing-in” requirements that other claims be truthful

and adequately substantiated. Violations of an administrative order can result in civil penalties

that accrue at the rate of $16,000 per violation, and can reach $1 million and higher. They are 15 16

thus a strong deterrent against future deceptive advertising. 

The majority of the Commission’s cases against deceptive supplement marketing in

recent years, however, have been brought in federal district court pursuant to Section 13(b) of

the FTC Act. This option allows the Commission to obtain both preliminary and permanent 17

injunctive relief as well as other equitable remedies, such as consumer redress or disgorgement
See, e.g., FTC v. Airborne Health, Inc., No. CV-08-05300 (C.D. Cal. final order Sept. 5, 18

2008) (up to $30 million for consumer redress program in connection with deceptive cold

prevention and treatment claims).

See, e.g., FTC v. 7 Day Mktg., Inc., No. CV08-01094-ER-FFM (C.D. Cal. final order 19

Feb. 17, 2008) (banning marketers of herbal colon cleanse to cure cancer from involvement in

any infomercial marketing).

FTC v. Airborne Health, Inc., No. CV-08-05300 (C.D. Cal. final order Sept. 5, 2008).

20

7

of ill-gotten gains. In cases of outright fraud or repeated law violations, the Commission has 18

sought bans on marketing of certain categories of products and the posting of performance

bonds.19

The Commission works to make sure its enforcement actions hold accountable not just

the supplement manufacturer but also other parties involved in the creation or dissemination of

the deceptive claims, including company owners and key officers, ad agencies, infomercial

producers, distributors, and retailers.

B. Recent Examples of Enforcement Efforts

In the past two years alone, the FTC has filed or settled 30 cases involving supplements

promoted with false or unsubstantiated claims for everything from the common cold to cancer. 

The Commission has also worked with FDA and foreign authorities to conduct Internet sweeps

targeting especially pervasive or pernicious trends. Recent sweeps have resulted in more than

130 warning letters by the FTC, followed by targeted law enforcement against those failing to

stop or modify claims. 

1. Representative Cases

 Airborne Health, Inc. and Other Cold and Flu Products: In 2008, the Commission

settled charges of false and unsubstantiated claims for Airborne effervescent tablets. The 20

marketers of Airborne engaged in a nationwide television and print campaign promoting
FTC v. Rite Aid Corp., No. 1:09-CV-01333-JEJ (M.D. Pa. final order July 13, 2009) 21

($500,000 for consumer redress).

FTC v. CVS Pharmacy, Inc., No. CA09-420 (D.R.I. final order Sept. 9, 2009) ($2.8 22

million for consumer redress).

FTC v. Walgreen Co., No. 1:10-CV-01813 (N.D. Ill. final order Mar. 29, 2010) ($5.97 23

million for consumer redress).

FTC v. Improvita Health Prods., Inc., No. 1:09-CV-00858 (N.D. Ohio final order Jan 8, 24

2010; order granting notice of dismissal of corporate defendant Mar. 25, 2010 ) ($565,000 in

monetary relief).

8

Airborne as clinically proven to prevent colds and flu and protect against exposure to germs in

crowded environments, like airplanes. The FTC lawsuit named not only the company, but also

the inventor of the product and her husband. The settlement required that the defendants

contribute up to an additional $6.5 million to a private class-action settlement, resulting in a total

of $30 million available for consumer redress. 

Airborne conducted such a successful marketing campaign that it spurred several private

label copycat cold remedy products. National retail chains replicated the supplement using

similar package claims and placing their products next to Airborne on the shelf. In response, the

Commission brought parallel cases in 2009 against three major retail chains, Rite Aid, CVS,

21 22

and Walgreen, as well as Improvita Health Products, a contract manufacturer and 23 24

distributor that sold the copycat supplement to several retail chains. Each of these additional

cases has settled with orders that include permanent injunctions and funds for consumer redress.

Direct Marketing Concepts, Inc.: An FTC lawsuit in federal district court against the

marketer of two dietary supplements, “Coral Calcium” and “Supreme Greens,” culminated in

court orders in 2009 against various defendants that included monetary judgments totaling nearly
FTC v. Direct Mktg. Concepts, Inc., No. 04-CV-11136-GAO (D. Mass. final order Aug. 25

13, 2009) (monetary judgment against multiple defendants totaling nearly $70 million).

FTC v. Roex, Inc., No. SACV09-0266 (C.D. Cal. final order Mar. 4, 2009) ($3 million 26

for consumer redress).

FTC v. Romeo, No. 2:09-CV-01262-WJM-CCC (D.N.J. filed Mar. 20, 2009). 27

9

$70 million. Infomercials for the products claimed they would cure many serious diseases, 25

including cancer, Parkinson’s, heart disease, and autoimmune disease. The order also addressed

the defendants’ failure to disclose that the promotional programming was, in fact, paid

advertising, and their practice of charging consumers on an ongoing basis without their consent.

Roex, Inc.: This Commission action involved an unusual marketing technique, with

products sold by means of a nationally broadcast, live call-in radio program titled “The Truth

About Nutrition.” The Commission settled charges against the company, its principal, and one 26

of the radio show hosts, for allegedly deceptive claims that an infrared sauna device would treat

cancer, and that various supplements would treat cancer, AIDS, diabetes, Alzheimer’s,

Parkinson’s, and other diseases. The order required the defendants to pay $3 million for

consumer redress. In March 2010, the Commission distributed refunds to more than 5,700

consumers with the average check totaling approximately $500.

David J. Romeo and Stella Labs, LLC: Deceptive weight loss claims have long plagued

the supplement industry. The Commission often sees a flurry of deceptive marketing campaigns

with each new weight loss ingredient introduced to the market. In this matter, the Commission

challenged claims made by a supplier of Hoodia gordonii, derived from a cactus plant native to

southern Africa, that the ingredient was a powerful appetite suppressant proven to reduce caloric

intake by 1,000 to 2,000 calories per day. The FTC complaint also charged the company with 27

selling fake hoodia to its trade customers who used the ingredient to manufacture weight loss
FTC v. Basic Research, LLC, No. 09-CV-972 (D. Utah filed Nov. 2, 2009). 28

10

supplements. The case is currently in litigation in federal district court. 

Basic Research, LLC: In another weight loss supplement case, involving a recidivist

already under order for the allegedly deceptive marketing of multiple dietary supplements, the

FTC has challenged claims for Relacore and Akävar 20/50, supplements that have been

promoted in national magazines with claims such as “eat all you want and still lose weight.”28

The Department of Justice, at the FTC’s request, filed suit in federal court last November,

charging the company and related parties with violating a 2006 FTC order that involved similar

deceptive weight loss marketing and imposed a $3 million judgment. The case is currently in

litigation. 

2. Enforcement Sweeps

While many of the FTC’s enforcement actions target individual supplement

manufacturers, the FTC often collaborates with FDA and international authorities to tackle

certain categories of health fraud more broadly. The FTC uses enforcement sweeps, for

example, to address widespread online marketing of products for serious health ailments, like

cancer or diabetes. Such marketing scams are particularly cruel by preying on consumers when

they are most vulnerable and desperate, offering false hope and even luring them away from

more effective treatments. For every serious disease, especially those with no proven cure, there

are hundreds of marketers engaging in such fraud, mostly through Internet marketing. 

The FTC also conducts sweeps to stop the fraudulent marketing that often follows any

new public health scare. In recent years, the FTC has seen a proliferation of products, including

dietary supplements, that purportedly protect against, treat, or cure anthrax, SARS, avian flu, and

H1N1 flu. The FTC has found that the best way to quickly shut down such scams is to issue
In coordination with the FTC, FDA issued warning letters to 28 U.S. companies and 29

two foreign individuals for marketing unapproved drugs, and the Canada Competition Bureau

sent warning letters to Canadian companies selling fraudulent cancer cures online.

See Press release, FTC Sweep Stops Peddlers of Bogus Cancer Cures (Sept. 18, 2008), 30

http://www2.ftc.gov/opa/2008/09/boguscures.shtm.

11

warning letters to as many of these marketers as possible and then follow with targeted cases, as

needed.

The FTC has also successfully used smaller scale enforcement sweeps to address

exaggerated or unfounded claims for the ingredient du jour in the supplement industry. These

might target the latest ingredient promising to cause effortless and dramatic weight loss, or to

treat the common cold, or to make children smarter. In such cases, bringing a group of parallel

law enforcement actions can be effective in curbing a deceptive marketing trend.

Operation False Cures - Cancer Sweep: The most recent of the FTC’s large-scale

Internet sweeps was an enforcement effort coordinated with FDA and the Canada Competition

Bureau. Initiated with an online surf for fraudulent cancer cure products in June 2007, the FTC

sent warning letters via e-mail to 112 Web sites marketing everything from essiac tea and other

herbal blends (some containing highly toxic herbs), to laetrile, shark cartilage, coral calcium,

mushroom extract, and black salve (a corrosive product that can cause burns and scarring) – all

promoted to prevent, cure, or treat cancer. Of the 112 sites contacted by the FTC, nearly 30 29

percent either shut down their sites or removed the cancer claims. The remainder were reviewed

to determine whether law enforcement was appropriate, with some referred to FDA or Canadian

authorities. The FTC followed this effort with 11 enforcement actions charging companies and

individuals with making false or unsubstantiated cancer claims, and in some cases even

misrepresenting that there was scientific proof that their products worked.30
One case was dismissed due to insufficient evidence that the repondents were

31

responsible for the Web site claims at issue.

See discussion infra, Section IV. 32

See Press release, FDA, FTC Warn Public of Fraudulent 2009 H1N1 Influenza Products 33

(May 1, 2009), http://www.ftc.gov/opa/2009/05/swineflu.shtm. The H1N1 Internet sweep was

the eleventh joint enforcement effort conducted by members of ICPEN, including both the FTC

and FDA.

12

As of this month, ten of those 11 cases have been successfully settled or litigated,

resulting in orders that bar future false or unsubstantiated claims and also require notification to

past customers informing them that little or no evidence exists to support the efficacy of the

products they purchased and urging them to consult with their doctors. Four of the settlements 31

also imposed monetary judgments. In addition to aggressively targeting Internet scammers

hawking fraudulent cancer cures, the Commission launched an innovative consumer education

campaign to teach consumers how to spot and report such scams.32

H1N1 Flu Sweep: The rapid spread of the H1N1 flu virus last year and mounting public

fears about the epidemic led to a spate of online marketing scams. The FTC worked with

members of the International Consumer Protection Enforcement Network (“ICPEN”) to conduct

an Internet surf that identified products – including supplements, homeopathic products, air

filtration devices, and cleaning agents – for curing, treating, and preventing the spread of the

H1N1 virus. As part of this sweep, the FTC sent warning letters to 20 Web site operators 33

making questionable claims and referred another 13 Web site operators, believed to be located

outside the U.S., to foreign law enforcement authorities. In addition, the FTC and FDA sent the

first joint warning letter to Weil Lifestyle LLC, regarding a dietary supplement containing the
See FTC/FDA Joint Warning Letter to Weil Lifestyle LLC (Oct. 15, 2009), 34

www.fda.gov/iceci/enforcementactions/warningletters/ucm186837.htm. In response to the joint

warning, Dr. Andrew Weil, the popular integrative medicine physician affiliated with the Web

site, agreed to drop or modify all identified claims.

See Press release, FTC Warns Marketers of Children’s Omega-3 Fatty Acid 35

Supplements that Claims About Brain and Vision Benefits May Be Deceptive (Feb. 16, 2010),

http://www.ftc.gov/opa/2010/02/omega.shtm.

See Northwest Natural Products, Inc., FTC File No. 092-3153, closing letter Oct. 30, 36

2009, http://www.ftc.gov/os/closings/091030northwestclosingletter.pdf.

13

herb astragalus that the company claimed could cure H1N1 infections. As with the cancer 34

sweep, the FTC also engaged in consumer outreach in the form of an alert to warn the public of

such scams.

Omega-3 for Children’s Brain and Vision Function: Most recently, the FTC identified

an increase in the number of Omega-3 fatty acid supplements and food products being promoted

for school-aged children’s brain and vision function and development. Many of the claims 35

include specific promises of increased intelligence, better focus, mood, memory, concentration,

and visual acuity – benefits that lack adequate scientific support. To address this trend, the

Commission staff sent letters to 11 companies, advising them to review their labeling and

advertising claims. In those letters, the FTC staff described its recent investigation into similar

claims by Northwest Natural Products, Inc. (“NNP”), the marketer of “L’il Critters Omega-3

Gummy Fish,” a children’s dietary supplement. The letters advised other marketers that NNP 36

had quickly modified its marketing materials to remove unsubstantiated claims and urged

recipients to take the same steps to ensure compliance. The FTC staff is now following up to

ensure appropriate responsive actions are taken.

IV. FTC Consumer Education Efforts

The Commission complements its law enforcement activities with a variety of innovative
See 37 http://www.ftc.gov/curious.

See FTC Consumer Alert: RX for Products that Claim to Prevent H1N1 (Nov. 2009), 38

http://www.ftc.gov/bcp/edu/pubs/consumer/alerts/alt083.shtm. A similar consumer alert was

also issued in connection with the FTC’s cases against Airborne and copycat cold prevention

supplements. See FTC Consumer Alert: Pills that Prevent the Common Cold? A Tough Claim

to Swallow (Aug. 2008), http://ftc.gov/bcp/edu/pubs/consumer/alerts/alt078.shtm.

14

education and outreach efforts for both consumers and industry. The FTC’s consumer outreach

has been especially strong on subjects related to health and safety. The agency routinely issues

consumer alerts, brochures, and uses other creative approaches, like YouTube videos and

Internet microsites, to help consumers safely navigate the supplement marketplace. 

For example, as an adjunct to its cancer cure sweep, the Commission launched a

campaign, “Cure-ious? Ask,” to alert consumers to cancer scams and encourage them to discuss

all treatment options with their doctors. The campaign has its own Web site, featuring a video, 37

with advice on how to spot and report questionable claims and a list of resources on cancer

treatments from a variety of government agencies. The Commission’s partners in this effort are

the American Society of Clinical Oncology, the Cleveland Clinic, and the National Association

of Free Clinics, all of whom are disseminating campaign information to both patients and

medical care practitioners. The campaign is also mentioned in numerous blogs related to cancer

and health.

The Commission also routinely issues consumer alerts, such as its alert in connection

with its H1N1 sweep, which warned consumers of deceptive sales pitches for H1N1 treatments,

and provided accurate information from the Centers for Disease Control and Prevention about

how H1N1 spreads and how to limit exposure to the virus.

38

Beyond these topic-specific consumer education efforts, the FTC has created several

general consumer education brochures related to health, safety, and the efficacy of dietary
 The booklet is available online at 39

http://www.ftc.gov/bcp/edu/pubs/consumer/health/hea17.pdf. Multiple print copies can be

ordered free of charge at http://bulkorder.ftc.gov/.

15

supplements. For example, the booklet “Who Cares: Sources of Information About Health Care

Products and Services” is aimed at older consumers, their families, and caregivers. It includes

information on dietary supplements, weight loss products, miracle cures, and alternative and

complementary medicine. These materials are regularly updated and supplemented with 39

assistance from the FDA, NIH/ODS, and other agencies. 

V. Conclusion 

The Commission will remain vigilant in protecting consumers against fraud and

deception in the dietary supplement market. The agency will continue to work closely with FDA

and other law enforcement partners to seek strong remedies against unscrupulous marketers. It

will also continue to reach out to supplement users to educate them about how to use

supplements safely, where to turn for reliable and accurate information about the benefits of

supplements, and how to avoid being scammed. The Commission appreciates this opportunity to

describe its efforts to the Committee.